Accéder au contenu
Merck

Tumor Interferon Signaling Is Regulated by a lncRNA INCR1 Transcribed from the PD-L1 Locus.

Molecular cell (2020-06-07)
Marco Mineo, Shawn M Lyons, Mykola Zdioruk, Niklas von Spreckelsen, Ruben Ferrer-Luna, Hirotaka Ito, Quazim A Alayo, Prakash Kharel, Alexandra Giantini Larsen, William Y Fan, Sophia Auduong, Korneel Grauwet, Carmela Passaro, Jasneet K Khalsa, Khalid Shah, David A Reardon, Keith L Ligon, Rameen Beroukhim, Hiroshi Nakashima, Pavel Ivanov, Paul J Anderson, Sean E Lawler, E Antonio Chiocca
RÉSUMÉ

Tumor interferon (IFN) signaling promotes PD-L1 expression to suppress T cell-mediated immunosurveillance. We identify the IFN-stimulated non-coding RNA 1 (INCR1) as a long noncoding RNA (lncRNA) transcribed from the PD-L1 locus and show that INCR1 controls IFNγ signaling in multiple tumor types. Silencing INCR1 decreases the expression of PD-L1, JAK2, and several other IFNγ-stimulated genes. INCR1 knockdown sensitizes tumor cells to cytotoxic T cell-mediated killing, improving CAR T cell therapy. We discover that PD-L1 and JAK2 transcripts are negatively regulated by binding to HNRNPH1, a nuclear ribonucleoprotein. The primary transcript of INCR1 binds HNRNPH1 to block its inhibitory effects on the neighboring genes PD-L1 and JAK2, enabling their expression. These findings introduce a mechanism of tumor IFNγ signaling regulation mediated by the lncRNA INCR1 and suggest a therapeutic target for cancer immunotherapy.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Sigma-Aldrich
Rosetta 2(DE3)pLysS Competent Cells - Novagen, Novagen′s Rosetta 2 (pLysS) host strains are BL21 derivatives designed to enhance the expression of eukaryotic proteins that contain codons rarely used in E. coli along with T7 lysozyme activity.